4.7 Review

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Journal

LANCET ONCOLOGY
Volume 15, Issue 9, Pages E395-E403

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(14)70011-7

Keywords

-

Categories

Funding

  1. Antisense Pharma
  2. Bayer
  3. Merck Serono
  4. Roche
  5. Abbvie
  6. MSD
  7. Mundipharma
  8. Magforce
  9. Apogenix
  10. Boehringer Ingelheim
  11. Eli Lilly

Ask authors/readers for more resources

This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available